Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer


Acquired | Acquired

About Eclat Pharmaceuticals

Eclat Pharmaceuticals focuses on the development, approval and commercialization of niche brands and generic products. In March 2012, Eclat Pharmaceuticals was acquired by Flamel Technologies. The valuation of Eclat Pharmaceuticals was undisclosed. Other terms of the deal were not released.

Eclat Pharmaceuticals Headquarter Location

699 Trade Center Blvd Suite A

Chesterfield, Missouri, 63005,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Eclat Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eclat Pharmaceuticals is included in 1 Expert Collection, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.